article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. These chemicals are everywhere and have been used in many ways over the decades, bringing a range of benefits from water- and stain-resistant coatings and firefighting foams to nail polish and food packaging.

article thumbnail

Alfasigma sets stage for Jyseleca in axSpA after Phase III win

Pharmaceutical Technology

GlobalData predicts the axSpA market across the seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will reach $3.6bn by 2028. Jyseleca in third development partnership The development of Jyseleca has seen several shifts in the pharmaceutical industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

As Trump Pharma Tariff Deadline Looms, Here's How the Sector Got Here

Pharmaceutical Commerce

24 The EU will also be investing $600 billion in the US and purchasing $750 billion worth of US energy exports through the year 2028. July 27 - Trump reached a formal trade agreement with the European Union in which a maximum 15% levy will be imposed on “most” EU exports, including autos and their parts; semiconductors; and pharmaceuticals.

article thumbnail

Revolution Medicines partners Royalty Pharma on $2bn funding

Pharmaceutical Technology

The first tranche will be received by Revolution, following US Food and Drug Administration (FDA) approval of daraxonrasib to treat metastatic PDAC by January 2028. The debt facility portion consists of three tranches totalling up to $750m linked directly to daraxonrasib’s commercial milestones. Sign up for our daily news round-up!

article thumbnail

Merck agrees to acquire Verona Pharma for $10bn

Pharmaceutical Technology

Keytruda, which brought in $30bn in revenue in 2024, is approaching patent expirations set in 2028, and Merck is therefore intensifying efforts to restructure its portfolio, according to a report by Reuters. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

article thumbnail

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

PharmTech

billion and an additional $2 billion in non-contingent anniversary payments through 2028. This news comes just 10 days after BioNTech announced a global co-development and co-commercialization agreement valued at up to $11.1 billion for BNT327 (2). Under that deal, BMS will provide BioNTech with an upfront payment of $1.5 References 1.

article thumbnail

Astria Therapeutics licenses navenibart rights to Kaken for HAE

Pharmaceutical Technology

Astria anticipates that its cash, cash equivalents and short-term investments will fund its current operating plan into 2028. Kaken will support the ALPHA-ORBIT Phase 3 trial in Japan and handle regulatory submissions. Give your business an edge with our leading industry insights.